ARTICLE | Clinical News
Piromelatine: Phase II started
October 10, 2016 7:00 AM UTC
Neurim began the double-blind, placebo-controlled, U.S. Phase II ReCOGNITION trial to evaluate 5, 20 and 50 mg oral piromelatine once daily for 26 weeks in about 500 patients treated with stable doses...